查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1871160

基因組學市場機會、成長促進因素、產業趨勢分析及預測（2025-2034年）

Genomics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球基因組學市場價值為 390 億美元，預計到 2034 年將以 15.4% 的複合年成長率成長至 1,620 億美元。

基因組學市場 - IMG1

基因組學產業正快速擴張，其發展動力源自於慢性病和遺傳性疾病日益普遍以及精準醫療的興起。基因組學透過分析生物體的全部DNA組成（包括所有基因），為疾病機制、基因變異和個人化治療方案的發展提供了變革性的見解。 DNA定序、基因編輯和生物資訊學等技術的進步，以及人工智慧和巨量資料分析的日益普及，進一步推動了基因組學市場的發展。基因組學在醫療保健和生命科學領域的應用，加速了其在診斷、藥物研發、生殖健康、法醫學和農業等領域的普及。如今，基因組學在腫瘤學、罕見疾病診斷、藥物基因組學和伴隨診斷等領域至關重要，醫療保健系統正日益整合基因組學工具，以實現標靶治療、減少藥物不良反應並簡化藥物研發流程。持續的監管支持，以及生技公司和研究機構之間的合作，正鞏固基因組學作為預測性和個人化醫療保健基石的地位。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 390億美元
預測值 1620億美元
複合年成長率 15.4%

2024年，產品板塊佔據67.1%的市場佔有率，預計到2034年將達到1,057億美元，年複合成長率達15.1%。此類別涵蓋科學研究和臨床應用中使用的關鍵儀器和耗材。聚合酶鍊式反應系統、微陣列和新一代定序平台等技術對於高效、準確、高通量地產生大尺度基因組資料至關重要。試劑、定序試劑盒和樣品製備材料等耗材具有重要價值，因為它們是實驗室流程中持續必需的。儀器和耗材技術的不斷升級正在推動其在醫院、學術研究和生物製藥行業的廣泛應用。

2024年，定序領域創造了148億美元的收入。這項技術仍然是關鍵的成長引擎，這得益於其在精確性、可擴展性和成本效益方面的進步。高通量定序方法能夠同時讀取大量的DNA和RNA序列，為基因組和轉錄組研究提供前所未有的細節。這些創新加速了科學發現，改善了疾病診斷，並擴展了定序在臨床應用中的作用，尤其是在精準醫療和基因篩檢領域。定序平台的持續進步正在確保其可近性，並使其更好地融入醫療保健和研究工作流程。

預計到2024年，北美基因組學市場佔有率將達到42.6%，這反映了其強大的研究生態系統、大量的政府和私人投資，以及基因組學在醫療保健領域的廣泛應用。該地區對精準醫療計劃的重視、活躍的臨床試驗活動以及生物技術機構與學術機構之間的合作，都為持續創新提供了支持。對個人化療法、先進診斷和疾病早期檢測技術的需求依然十分旺盛。隨著各大公司在定序、生物資訊學和診斷技術方面取得領先進展，北美正透過創新和普及性，持續塑造全球基因組學格局。

全球基因體學市場的主要參與者包括賽默飛世爾科技（Thermo Fisher Scientific）、凱傑（QIAGEN）、安捷倫科技（Agilent Technologies）、牛津奈米孔科技公司（Oxford Nanopore Technologies）、Bio-Rad Laboratories、丹納赫（Danaher）、羅氏（F. Hoffy） Genetics）、華大基因（BGI Genomics）、艾本多夫（Eppendorf）、科樂基因（Color Genomics）、太平洋生物科學公司（Pacific Biosciences of California）、英偉達（NVIDIA）、奎斯特診斷（Quest Diagnostics）和艾魯米納（Illumina）。為了鞏固自身地位，基因組學產業的主要參與者正積極推行以技術創新、合作和擴張為核心的策略。各公司正大力投資先進的定序平台和基於雲端的生物資訊工具，以提高資料的精確性和可近性。與製藥公司和研究機構的策略合作正在推動基因組學在藥物研發和臨床試驗中的應用。

目錄

第1章：方法論與範圍

第2章：執行概要

第3章：行業洞察

  • 產業生態系分析
    • 供應商格局
    • 每個階段的價值增加
    • 影響價值鏈的因素
  • 產業影響因素
    • 成長促進因素
      • 遺傳性和慢性疾病的盛行率不斷上升
      • DNA定序與基因編輯技術的進步
      • 精準醫療的日益普及
      • 政府對基因組學研究的計劃和資助
    • 產業陷阱與挑戰
      • 基因資料相關的倫理和隱私問題
      • 高成本和可負擔性問題
    • 市場機遇
      • 開發經濟高效且快速的定序技術
      • 人工智慧與機器學習的融合以增強基因組資料分析
  • 成長潛力分析
  • 監管環境
    • 北美洲
      • 美國
      • 加拿大
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 技術格局
    • 當前技術趨勢
    • 新興技術
  • 未來市場趨勢
  • 管道分析
  • 波特的分析
  • PESTEL 分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
    • 全球的
    • 北美洲
    • 歐洲
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 擴張計劃

第5章：市場估算與預測：依類型分類，2021-2034年

  • 主要趨勢
  • 產品
    • 儀器
    • 耗材和試劑
  • 服務
    • 基於NGS的服務
    • 核心基因組學服務
    • 生物標記翻譯服務
    • 計算服務
    • 其他服務

第6章：市場估計與預測：依技術分類，2021-2034年

  • 主要趨勢
  • PCR（聚合酶鍊式反應）
  • 定序
  • 微陣列
  • 核酸萃取與純化
  • 其他技術

第7章：市場估計與預測：依應用領域分類，2021-2034年

  • 主要趨勢
  • 診斷
  • 藥物發現與開發
  • 精準醫療
  • 農業和動物研究
  • 其他應用

第8章：市場估算與預測：依最終用途分類，2021-2034年

  • 主要趨勢
  • 醫院和診所
  • 研究中心、學術機構和政府機構
  • 製藥和生物技術公司
  • 其他最終用途

第9章：市場估計與預測：依地區分類，2021-2034年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：公司簡介

  • Agilent Technologies
  • BGI Genomics
  • Bio-Rad Laboratories
  • Color Genomics
  • Danaher
  • Eppendorf
  • Eurofins Scientific
  • F. Hoffmann-La Roche
  • Illumina
  • Myriad Genetics
  • NVIDIA
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California
  • QIAGEN
  • Quest Diagnostics
  • Thermo Fisher Scientific
簡介目錄
Product Code: 14946

The Global Genomics Market was valued at USD 39 Billion in 2024 and is estimated to grow at a CAGR of 15.4% to reach USD 162 Billion by 2034.

Genomics Market - IMG1

The genomics industry is expanding swiftly, driven by the increasing prevalence of chronic and genetic disorders and the heightened emphasis on precision medicine. Genomics, which examines an organism's full DNA makeup, including all genes, offers transformative insights into disease mechanisms, genetic variations, and individualized treatment pathways. The market's momentum is further supported by technological progress in DNA sequencing, gene editing, and bioinformatics, along with the growing application of artificial intelligence and big data analytics. The use of genomics across healthcare and life sciences has accelerated its adoption in diagnostics, drug discovery, reproductive health, forensics, and agriculture. With genomics now vital to areas such as oncology, rare disease diagnosis, pharmacogenomics, and companion diagnostics, healthcare systems are increasingly integrating genomic tools to enable targeted therapies, reduce adverse drug reactions, and streamline drug development. Continuous regulatory support, combined with collaborative efforts between biotechnology firms and research institutions, is reinforcing genomics as the foundation of predictive and personalized healthcare.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$39 Billion
Forecast Value$162 Billion
CAGR15.4%

The products segment held 67.1% share in 2024 and is expected to reach USD 105.7 Billion by 2034, growing at a CAGR of 15.1%. This category includes essential instruments and consumables used in research and clinical applications. Technologies such as polymerase chain reaction systems, microarrays, and next-generation sequencing platforms are central to generating large-scale genomic data with improved efficiency, accuracy, and throughput. Consumables, including reagents, sequencing kits, and sample preparation materials, hold significant value as they are continuously required for laboratory processes. The ongoing technological upgrades in both instruments and consumables are helping expand their adoption in hospitals, academic research, and biopharmaceutical industries.

The sequencing segment generated USD 14.8 Billion in 2024. This technology remains a key growth engine, supported by advancements in precision, scalability, and cost-effectiveness. High-throughput sequencing methods enable simultaneous reading of extensive DNA and RNA sequences, offering unparalleled detail for genome and transcriptome studies. These innovations have accelerated scientific discovery, improved disease diagnosis, and expanded the role of sequencing in clinical applications, particularly in precision medicine and genetic screening. Continuous progress in sequencing platforms is ensuring their accessibility and integration into healthcare and research workflows.

North America Genomics Market held a 42.6% share in 2024, reflecting its strong research ecosystem, significant government and private investment, and widespread adoption of genomics in healthcare. The region's focus on precision medicine initiatives, robust clinical trial activity, and collaborations between biotechnology and academic institutions support continuous innovation. The demand for personalized therapies, advanced diagnostics, and early disease detection technologies remains particularly high. With major companies leading advancements in sequencing, bioinformatics, and diagnostic technologies, North America continues to shape the global genomics landscape through innovation and accessibility.

Leading companies operating in the Global Genomics Market include Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Oxford Nanopore Technologies, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche, Eurofins Scientific, Myriad Genetics, BGI Genomics, Eppendorf, Color Genomics, Pacific Biosciences of California, NVIDIA, Quest Diagnostics, and Illumina. To strengthen their position, major players in the genomics industry are pursuing strategies centered on technology innovation, partnerships, and expansion. Companies are investing heavily in advanced sequencing platforms and cloud-based bioinformatics tools to enhance data precision and accessibility. Strategic collaborations with pharmaceutical firms and research institutions are enabling the integration of genomics in drug discovery and clinical trials.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Type trends
    • 2.2.3 Technology trends
    • 2.2.4 Application trends
    • 2.2.5 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factors affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of genetic and chronic diseases
      • 3.2.1.2 Advancements in DNA sequencing and gene editing technologies
      • 3.2.1.3 Increasing adoption of precision medicine
      • 3.2.1.4 Government initiatives and funding for genomics research
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Ethical and privacy concerns around genetic data
      • 3.2.2.2 High cost and affordability issues
    • 3.2.3 Market opportunities
      • 3.2.3.1 Development of affordable and rapid sequencing technologies
      • 3.2.3.2 Integration of AI and machine learning for enhanced genomic data analysis
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
      • 3.4.1.1 U.S.
      • 3.4.1.2 Canada
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Future market trends
  • 3.7 Pipeline analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Products
    • 5.2.1 Instruments
    • 5.2.2 Consumables and reagents
  • 5.3 Services
    • 5.3.1 NGS-based services
    • 5.3.2 Core genomics services
    • 5.3.3 Biomarker translation services
    • 5.3.4 Computational services
    • 5.3.5 Other services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 PCR (polymerase chain reaction)
  • 6.3 Sequencing
  • 6.4 Microarray
  • 6.5 Nucleic acid extraction and purification
  • 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Diagnostics
  • 7.3 Drug discovery and development
  • 7.4 Precision medicine
  • 7.5 Agriculture and animal research
  • 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Research centers and academic and government institutes
  • 8.4 Pharmaceutical and biotechnology companies
  • 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 India
    • 9.4.3 Japan
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Agilent Technologies
  • 10.2 BGI Genomics
  • 10.3 Bio-Rad Laboratories
  • 10.4 Color Genomics
  • 10.5 Danaher
  • 10.6 Eppendorf
  • 10.7 Eurofins Scientific
  • 10.8 F. Hoffmann-La Roche
  • 10.9 Illumina
  • 10.10 Myriad Genetics
  • 10.11 NVIDIA
  • 10.12 Oxford Nanopore Technologies
  • 10.13 Pacific Biosciences of California
  • 10.14 QIAGEN
  • 10.15 Quest Diagnostics
  • 10.16 Thermo Fisher Scientific